PharmiWeb.com - Global Pharma News & Resources

Biotech - Press Releases

Date Title Company
08-Nov-2022 Orgenesis secures up to USD 50 Million subsidiary-level investment from Metalmark Capital to accelerate growth of Point-of-Care services Orgenesis
08-Nov-2022 Enara Bio highlights Dark Antigens™ as a novel class of targets for developing targeted immunotherapies against solid tumors Enara Bio
08-Nov-2022 Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Cutaneous T-Cell Lymphoma Cartherics
08-Nov-2022 Oligonucleotide Synthesis Market 2022 Global Analysis, Opportunities, Size, Trends, Growth and Forecast 2026 Markets and Markets
08-Nov-2022 Protein Expression Market - How The Market Will Witness Substantial Growth In The Upcoming Years Markets and Markets
07-Nov-2022 Australia’s Telix Pharmaceuticals Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study Telix Pharmaceuticals
07-Nov-2022 Full-Scale PROTAC In Vivo Evaluation Services to Facilitate PROTAC Drug R&D BOC Sciences
05-Nov-2022 Alfa Chemistry Testing Lab: Analytical Testing is Now A Must for the Flourishing Coffee Industry Alfa Chemistry Testing Lab
04-Nov-2022 Pronalyse Supports Drug Discovery with the Launch of Biosimilar Analysis Solutions Creative Proteomics
04-Nov-2022 Creative Proteomics Boosts Your Project with Unknown Metabolite Identification Services Creative Proteomics
04-Nov-2022 Creative Proteomics Cytokine Announces the Launch of Chemokine Detection Service Creative Proteomics
03-Nov-2022 Mesenchymal Stem Cells Market is estimated to be US$ 9.17 billion by 2032 with a CAGR of 12.8% during the forecast period Prophecy Market Insights
03-Nov-2022 Creative Enzymes Expands Its Probiotic Portfolio Creative Enzymes
03-Nov-2022 Creative Enzymes Launches Raw Materials for Manufacturing Diagnostic Kits Creative Enzymes
02-Nov-2022 CV6 Therapeutics Secures $9.2m to Progress Novel Cancer Drug to Phase 1a Trial CV6 Therapeutics
02-Nov-2022 BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma BeiGene
02-Nov-2022 Oncovita presents preclinical data on its promising MVdeltaC oncolytic vaccine at SITC Annual Meeting 2022 Andrew Lloyd Associates
02-Nov-2022 Alderaan Biotechnology presents latest developments in next generation anti-CD25 antibody at SITC Congress Andrew Lloyd Associates
02-Nov-2022 CV6 Therapeutics Secures $9.2m to Progress Novel Cancer Drug to Phase 1a Trial CV6 Therapeutics
02-Nov-2022 Positive results from AELIX’ HIV therapeutic vaccine clinical study published in Nature Medicine Andrew Lloyd Associates